For nearly 150 years after Augustus Waller first described the orderly disintegration of severed nerve fibers in 1850, axon degeneration was assumed to be a passive process — the inevitable starvation of a cellular limb cut off from its soma. That assumption collapsed when researchers identified SARM1, a single enzyme whose activation is both necessary and sufficient to execute axon destruction by catastrophically consuming neuronal NAD+. SARM1 transformed Wallerian degeneration from passive decay into a programmed, druggable axonal death pathway — and recast NAD+ itself as the central molecular switch between axon survival and demise.
What Is SARM1?
SARM1 (Sterile Alpha and TIR Motif containing 1) is a 724-amino-acid enzyme expressed predominantly in neurons, with particularly high abundance in axons. Structurally, it contains three key domains: an N-terminal armadillo (ARM) domain that functions as an auto-inhibitory regulator, two sterile alpha motif (SAM) domains that mediate octamerization, and a C-terminal Toll/Interleukin-1 Receptor (TIR) domain that carries the enzymatic activity. Although SARM1 was originally classified as a TIR-domain adaptor in innate immune signaling, its dominant physiological role is as the executioner of axonal degeneration.[1]
The pivotal discovery came in 2012, when Osterloh and colleagues showed that loss of SARM1 in mice produced one of the most robust phenotypes in neuroscience: severed axons remained morphologically and functionally intact for weeks rather than degenerating within hours.[1] This single-gene knockout phenocopied the spontaneous WldS mutant, anchoring SARM1 as the long-sought executioner of Wallerian degeneration.
How SARM1 Works
NAD+ Hydrolase Activity: The TIR domain of SARM1 is itself a glycohydrolase. Once activated, it cleaves NAD+ into nicotinamide and ADP-ribose (along with small amounts of cyclic ADP-ribose), depleting the axonal NAD+ pool within minutes. This collapse of NAD+ halts glycolysis, ATP synthesis, and ion pumping — culminating in calcium influx, cytoskeletal fragmentation, and axon disassembly.[2]
NMN/NAD+ Ratio as the Activation Switch: SARM1 is allosterically regulated by the ratio of nicotinamide mononucleotide (NMN) to NAD+. In healthy axons, NMN adenylyltransferase 2 (NMNAT2) rapidly converts NMN into NAD+, keeping the ratio low and SARM1 auto-inhibited. NMNAT2 is short-lived and must be continuously transported from the cell body. When axons are injured or NMNAT2 supply fails, NMN accumulates and NAD+ falls — the rising NMN/NAD+ ratio binds the ARM domain, releases auto-inhibition, and triggers TIR-domain catalysis.[3]
Octamerization and Feed-Forward Activation: Cryo-EM studies revealed SARM1 assembles as an octameric ring. The ARM domains hold the TIR domains apart in the inactive state; ligand-driven conformational change permits TIR-TIR association, which is required for catalysis. This switch-like architecture makes axonal commitment to degeneration essentially all-or-none once a threshold is crossed.[4]
WldS and the NMNAT Connection: The slow Wallerian degeneration (WldS) mouse — discovered serendipitously in 1989 — owes its remarkable axon protection to a chimeric protein containing NMNAT1 that is mislocalized to axons, where it supplements NMNAT2 activity. By preserving NAD+ synthesis and lowering NMN, WldS keeps SARM1 silent. This was the first genetic clue that axon survival depends on NAD+ homeostasis, not on the cell body.[1]
Clinical Evidence and Research Findings
Peripheral Neuropathy: SARM1 deletion protects against axon loss in multiple models of peripheral neuropathy, including chemotherapy-induced peripheral neuropathy from vincristine and paclitaxel, traumatic nerve injury, and diabetic neuropathy. These models share a final common pathway: impaired axonal NMNAT2 function, NMN accumulation, and SARM1-driven NAD+ collapse.[2]
Traumatic Brain and Spinal Injury: In rodent models of traumatic axonal injury, SARM1 knockout markedly preserves white matter integrity, axonal continuity, and functional recovery. Because diffuse axonal injury is a major driver of post-concussive and post-traumatic cognitive dysfunction, SARM1 has emerged as a leading molecular target in neurotrauma.[2]
Glaucoma and Optic Neuropathy: Retinal ganglion cell axons in the optic nerve are particularly vulnerable to NAD+ decline with age and intraocular pressure stress. SARM1 deletion in mouse glaucoma models preserves optic nerve axons despite ongoing pressure elevation, supporting a model in which NAD+ depletion — not pressure itself — is the proximate driver of axon loss.[5]
Human Genetic Validation: Whole-exome sequencing in patients with sporadic and familial amyotrophic lateral sclerosis (ALS) has identified rare SARM1 coding variants that produce constitutively active, hyperactive enzyme. Carriers show NMN-independent SARM1 activation, providing the first direct human genetic evidence that gain-of-function SARM1 activity contributes to motor neuron disease.[3]
Chemotherapy-Induced Peripheral Neuropathy (CIPN): Preclinical and early translational work has shown that pharmacological SARM1 inhibitors prevent vincristine- and paclitaxel-induced axonopathy in cultured human iPSC-derived sensory neurons and in rodents, without compromising tumor cell killing. Several small-molecule SARM1 inhibitors have advanced into clinical-stage development for CIPN and related indications.[2]
Safety Profile and Translational Considerations
SARM1 knockout mice are viable, fertile, and live normal lifespans, with no overt baseline neurological phenotype — a critical pharmacological asset, suggesting that even chronic SARM1 inhibition is likely to be well tolerated. The principal theoretical concern is that SARM1 contributes to clearance of mildly damaged or developmentally inappropriate axons; long-term inhibition could in principle preserve dysfunctional fibers. However, no such phenotype has been observed in genetic models followed for extended periods.[1]
A subtler concern is innate immune signaling. SARM1’s TIR domain has been implicated in modulating MyD88-dependent pathways, and complete inhibition could in theory affect cytokine responses to certain pathogens. Clinical-stage inhibitors have been engineered for high selectivity and CNS penetrance, and early human safety data have not flagged immune-related adverse events.
SARM1 Inhibition vs Other Neuroprotective Approaches
NAD+ Precursor Supplementation (NR, NMN): Boosting NAD+ with nicotinamide riboside or NMN raises systemic NAD+ but has limited ability to prevent the catastrophic axonal NAD+ collapse driven by activated SARM1. Once the octameric enzyme is engaged, it can consume NAD+ faster than salvage pathways can replenish it. Importantly, exogenous NMN can paradoxically activate SARM1 in vulnerable axons by raising the NMN/NAD+ ratio. SARM1 inhibition acts upstream of NAD+ depletion and is therefore mechanistically more direct for axon preservation.[3]
Neurotrophic Factors: NGF, BDNF, and GDNF act primarily at the soma to support neuronal survival but have limited capacity to halt local axonal NAD+ collapse once initiated. They also face well-known delivery challenges across the blood-brain barrier.
Calcium and Calpain Inhibitors: Calcium influx and calpain activation are downstream of SARM1-driven NAD+ depletion. Blocking them addresses the executioner phase but not the upstream metabolic trigger.
NMNAT2 Stabilization: An alternative upstream strategy is to extend NMNAT2 half-life, keeping NMN low and SARM1 silent. This is mechanistically elegant but pharmacologically more challenging than direct enzyme inhibition.[4]
SARM1 inhibitors thus occupy a unique therapeutic niche: they are the only agents that directly disarm the axonal demolition enzyme, preserving NAD+ where it matters most — inside the axon — across a remarkably broad set of insults including trauma, chemotherapy, metabolic stress, and neurodegenerative disease.
References
- Osterloh JM, et al. “dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.” Science. 2012;337(6093):481-484.
- Gerdts J, et al. “SARM1 activation triggers axon degeneration locally via NAD+ destruction.” Science. 2015;348(6233):453-457.
- Figley MD, et al. “SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.” Neuron. 2021;109(7):1118-1136.
- Figley MD, DiAntonio A. “The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease.” Current Opinion in Neurobiology. 2020;63:59-66.
- Ko KW, Milbrandt J, DiAntonio A. “SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration.” Journal of Cell Biology. 2020;219(8):e201912047.
